Drug intelligence / Profile preview

5-fluorouracil + dipyridamole

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

5-fluorouracil + dipyridamole is a chemotherapy combination where dipyridamole acts as a modulator to enhance the cytotoxicity of 5-fluorouracil. Dipyridamole, an inhibitor of nucleoside transport, increases the activity of 5-fluorouracil in a dose-dependent manner. The combination has been studied in Phase I and II clinical trials for various cancer types, including advanced refractory malignancies, breast cancer, and transitional cell carcinoma. In clinical studies, dipyridamole has been administered both orally and intravenously in combination with 5-FU, often with the addition of folinic acid (leucovorin) to further enhance efficacy.

Other names: 5-FU + dipyridamole

Targets

TS (Thymidylate synthase)ENT1 (Solute carrier family 29 member 1)

Beyond the preview

Go deeper on 5-fluorouracil + dipyridamole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + dipyridamole.

Explore the full profile